These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35814516)

  • 21. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
    Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
    J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease.
    Mazhar IJ; Yasir M; Sarfraz S; Shlaghya G; Narayana SH; Mushtaq U; Shaman Ameen B; Nie C; Nechi D; Penumetcha SS
    Cureus; 2023 Aug; 15(8):e43635. PubMed ID: 37719477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis.
    Patikorn C; Veettil SK; Phisalprapa P; Pham T; Kowdley KV; Chaiyakunapruk N
    Ann Hepatol; 2021; 24():100315. PubMed ID: 33515800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
    Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
    Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.
    Han MAT; Altayar O; Hamdeh S; Takyar V; Rotman Y; Etzion O; Lefebvre E; Safadi R; Ratziu V; Prokop LJ; Murad MH; Noureddin M
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):616-629.e26. PubMed ID: 29913275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.
    Balakrishnan M; Patel P; Dunn-Valadez S; Dao C; Khan V; Ali H; El-Serag L; Hernaez R; Sisson A; Thrift AP; Liu Y; El-Serag HB; Kanwal F
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):61-71.e15. PubMed ID: 32360810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
    Mathews SE; Kumar RB; Shukla AP
    Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of drugs for nonalcoholic steatohepatitis.
    Shen B; Lu LG
    J Dig Dis; 2021 Feb; 22(2):72-82. PubMed ID: 33385317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dutta D; Kamrul-Hasan ABM; Mondal E; Nagendra L; Joshi A; Bhattacharya S
    Endocr Pract; 2024 Jul; 30(7):631-638. PubMed ID: 38697306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin E and nonalcoholic fatty liver disease.
    Pacana T; Sanyal AJ
    Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
    Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
    Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
    Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
    Singh S; Allen AM; Wang Z; Prokop LJ; Murad MH; Loomba R
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):643-54.e1-9; quiz e39-40. PubMed ID: 24768810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
    An J; Sohn JH
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.
    Mantovani A; Petracca G; Beatrice G; Csermely A; Lonardo A; Targher G
    Metabolites; 2021 Jan; 11(2):. PubMed ID: 33513761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.